PDF(Pubmed)
Abstract：
UNASSIGNED: Accounting for 15-20% of all meningiomas, WHO grade II meningiomas represent an intermediate group regarding risk of tumor recurrence. However, even within this subgroup varying clinical courses are observed with potential occurrence of multiple recurrences. Recently, DNA methylation profiles showed their value for distinguishing biological behaviors in meningiomas. Therefore, aim of this study was to investigate DNA methylation profiles in WHO grade II meningiomas.
UNASSIGNED: All patients that underwent resection of WHO grade II meningiomas between 1993 and 2015 were screened for a dismal course clinical course with ≥2 recurrences. These were matched to control cases with benign clinical courses without tumor recurrence. DNA methylation was assessed using the Infinium Methylation EPIC BeadChip microarray. Unsupervised hierarchical clustering was performed for identification of DNA methylation profiles associated with such a dismal clinical course.
UNASSIGNED: Overall, 11 patients with WHO grade II meningiomas with ≥2 recurrences (Group dismal) and matched 11 patients without tumor recurrence (Group benign) were identified. DNA methylation profiles revealed 3 clusters-one comprising only patients of group dismal, a second cluster comprising mainly patients from group benign and a third cluster comprising one group dismal and one group benign patient. Based on differential methylation pattern associations with the Wnt and the related cadherin signaling pathway was observed.
UNASSIGNED: DNA methylation clustering showed remarkable differences between two matched subgroups of WHO grade II meningiomas. Thus, DNA methylation profiles may have the potential to support prognostic considerations regarding meningioma recurrence and radiotherapeutic treatment allocation after surgical resection.
UNASSIGNED: All patients that underwent resection of WHO grade II meningiomas between 1993 and 2015 were screened for a dismal course clinical course with ≥2 recurrences. These were matched to control cases with benign clinical courses without tumor recurrence. DNA methylation was assessed using the Infinium Methylation EPIC BeadChip microarray. Unsupervised hierarchical clustering was performed for identification of DNA methylation profiles associated with such a dismal clinical course.
UNASSIGNED: Overall, 11 patients with WHO grade II meningiomas with ≥2 recurrences (Group dismal) and matched 11 patients without tumor recurrence (Group benign) were identified. DNA methylation profiles revealed 3 clusters-one comprising only patients of group dismal, a second cluster comprising mainly patients from group benign and a third cluster comprising one group dismal and one group benign patient. Based on differential methylation pattern associations with the Wnt and the related cadherin signaling pathway was observed.
UNASSIGNED: DNA methylation clustering showed remarkable differences between two matched subgroups of WHO grade II meningiomas. Thus, DNA methylation profiles may have the potential to support prognostic considerations regarding meningioma recurrence and radiotherapeutic treatment allocation after surgical resection.
摘要：
未经批准：占所有脑膜瘤的15-20％，WHOII级脑膜瘤代表肿瘤复发风险的中间组。然而,即使在这个亚组中，也观察到不同的临床疗程，并有可能发生多次复发。最近,DNA甲基化谱显示了它们对区分脑膜瘤生物学行为的价值。因此,这项研究的目的是调查WHOII级脑膜瘤的DNA甲基化谱。
UNASSIGNED：在1993年至2015年期间接受WHOII级脑膜瘤切除术的所有患者均接受了预后不佳的临床病程筛查，复发≥2次。这些病例与良性临床病程无肿瘤复发的对照病例相匹配。使用Infinium甲基化EPICBeadChip微阵列评估DNA甲基化。进行无监督分层聚类以鉴定与这种令人沮丧的临床过程相关的DNA甲基化谱。
未经评估：总的来说，确定了11例复发≥2次的WHOII级脑膜瘤患者（令人沮丧的组）和11例无肿瘤复发的患者（良性组）。DNA甲基化谱显示3个簇-一个仅包含令人沮丧的组患者，第二集群主要包括来自良性组的患者,以及第三集群包括一组令人沮丧的患者和一组良性患者。基于差异甲基化模式，观察到与Wnt和相关钙粘蛋白信号通路的关联。
UNASSIGNED：DNA甲基化聚类显示WHOII级脑膜瘤的两个匹配亚组之间存在显著差异。因此，DNA甲基化谱可能有可能支持有关脑膜瘤复发和手术切除后放射治疗分配的预后考虑。
UNASSIGNED：在1993年至2015年期间接受WHOII级脑膜瘤切除术的所有患者均接受了预后不佳的临床病程筛查，复发≥2次。这些病例与良性临床病程无肿瘤复发的对照病例相匹配。使用Infinium甲基化EPICBeadChip微阵列评估DNA甲基化。进行无监督分层聚类以鉴定与这种令人沮丧的临床过程相关的DNA甲基化谱。
未经评估：总的来说，确定了11例复发≥2次的WHOII级脑膜瘤患者（令人沮丧的组）和11例无肿瘤复发的患者（良性组）。DNA甲基化谱显示3个簇-一个仅包含令人沮丧的组患者，第二集群主要包括来自良性组的患者,以及第三集群包括一组令人沮丧的患者和一组良性患者。基于差异甲基化模式，观察到与Wnt和相关钙粘蛋白信号通路的关联。
UNASSIGNED：DNA甲基化聚类显示WHOII级脑膜瘤的两个匹配亚组之间存在显著差异。因此，DNA甲基化谱可能有可能支持有关脑膜瘤复发和手术切除后放射治疗分配的预后考虑。
